SAN DIEGO--(BUSINESS WIRE)--March 29, 2006--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has signed a cooperative research agreement with Commonwealth Biotechnologies, Inc. (CBI). Under the agreement, Aethlon and CBI will collaborate to pursue federal grant and research opportunities for the Aethlon Hemopurifier(TM) within biodefense and pandemic preparedness programs. Since 1999, Commonwealth researchers have managed or participated in awarded biodefense grants exceeding $20,000,000 in value. CBI also operates a secure BSL-3 containment facility able to receive and work with select agents as defined by the Centers for Disease Control (CDC).
